{"id":"W1525555980","doi":"10.1038/leu.2015.168","title":"BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","year":2015,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Imatinib; Medicine; Nilotinib; Internal medicine; Myeloid leukemia; Tyrosine-kinase inhibitor; Oncology; Imatinib mesylate; Mutation; Biology; Cancer; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003573312,0.0008355803,0.001082023,0.000402817,0.0002498718,0.00006405065,0.0002397555,0.0003098719,0.0002559024],"category_scores_gemma":[0.0001602991,0.0006145873,0.0001582669,0.0006398921,0.0001336689,0.0003330284,0.0000834837,0.0003488272,0.000190314],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1627825,"about_ca_system_score_gemma":0.03273449,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008057015,"about_ca_topic_score_gemma":0.005948204,"domain_scores_codex":[0.9958072,0.00006457478,0.001130267,0.001087457,0.0007046377,0.001205829],"domain_scores_gemma":[0.9976711,0.0002335286,0.0004214536,0.0008533834,0.0002270223,0.0005935314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.05828197,0.004353383,0.01234621,0.00899437,0.004636974,0.009753504,0.03456958,0.09851523,0.02645482,0.0002072296,0.003388201,0.7384985],"study_design_scores_gemma":[0.5074535,0.03990821,0.01234051,0.004574588,0.001336363,0.002520256,0.001348446,0.1102213,0.2341951,0.0001270855,0.08308564,0.002889058],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920561,0.001282667,0.001104761,0.0002377531,0.000197208,0.004012774,0.00005300401,0.0002901137,0.000765561],"genre_scores_gemma":[0.977075,0.0002463929,0.01203673,0.0001104398,0.0007663519,0.002527658,0.001073373,0.0001980096,0.005966084],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7356095,"threshold_uncertainty_score":0.9996306,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04711676767517604,"score_gpt":0.3224659356603377,"score_spread":0.2753491679851617,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}